Compare HRTG & IRWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HRTG | IRWD |
|---|---|---|
| Founded | 2012 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 670.9M | 713.8M |
| IPO Year | 2014 | 2009 |
| Metric | HRTG | IRWD |
|---|---|---|
| Price | $34.42 | $4.10 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 3 |
| Target Price | ★ $33.50 | $7.67 |
| AVG Volume (30 Days) | 232.5K | ★ 1.6M |
| Earning Date | 05-07-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 214.43 | ★ 1400.00 |
| EPS | ★ 3.23 | 0.55 |
| Revenue | ★ $847,330,000.00 | $298,276,000.00 |
| Revenue This Year | $7.50 | $57.95 |
| Revenue Next Year | $6.74 | $4.39 |
| P/E Ratio | $10.54 | ★ $7.40 |
| Revenue Growth | 3.71 | ★ 8.88 |
| 52 Week Low | $20.48 | $1.23 |
| 52 Week High | $36.50 | $5.78 |
| Indicator | HRTG | IRWD |
|---|---|---|
| Relative Strength Index (RSI) | 59.15 | 43.29 |
| Support Level | $25.34 | $3.89 |
| Resistance Level | $36.06 | $4.53 |
| Average True Range (ATR) | 1.03 | 0.17 |
| MACD | -0.22 | -0.04 |
| Stochastic Oscillator | 43.11 | 8.33 |
Heritage Insurance Holdings Inc is a regional property and casualty insurance company that offers a variety of personal and commercial insurance products. Through its subsidiaries, Heritage Property & Casualty Insurance, Narragansett Bay Insurance, and Zephyr Insurance, the company issues personal residential property insurance across various states in the U.S. It also offers commercial residential insurance predominantly for its Florida properties. Heritage Insurance manages insurance underwriting, customer services, actuarial analysis, distribution, and claims processing internally. The company operates in Alabama, California, Connecticut, Delaware, Florida, Georgia, Hawaii, Maryland, Massachusetts, Mississippi, New Jersey, New York, North Carolina, Rhode Island, and South Carolina.
Ironwood Pharmaceuticals Inc is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal, or GI, and rare diseases. It is focused on the development and commercialization of inventive product opportunities in areas of unmet need, leveraging its demonstrated expertise and capabilities in GI and rare diseases. LINZESS is its commercial product. LINZESS is also available for the treatment of adults with IBS-C or CIC in Mexico, adults with IBS-C or chronic constipation in Japan, and adults with IBS-C in China. Linaclotide is available under the trademarked name CONSTELLA for the treatment of adults with IBS-C or CIC and pediatric patients ages 6-17 years old with FC in Canada, and to adults with IBS-C in certain European countries.